课题基金 / 基金详情

项目摘要

项目成果

CARL D NOVINA的其他基金

相似基金

相关文献

中文摘要
翻译
描述(由申请人提供):融合到限制性内切酶的定制DNA结合域的出现改变了
英文摘要
DESCRIPTION (provided by applicant): The advent of custom built DNA binding domains fused to restriction enzymes changed the landscape of biomedical research and heralded a new age in gene therapy. This fact is highlighted by Phase I clinical trials in which zinc finger nucleases are being used to knockout the CCR5 receptor in CD34+ T cells of HIV infected individuals to generate HIV-resistant T cells (clinical trial #NCT00842634). In addition to targeted gene knockout, other biomedical applications of the “designer nucleases” are gene correction and gene activation. However, gene correction requires homologous recombination following a DNA cut – a very inefficient process – and current strategies for stable gene activation require constitutive expression of an ectopic protein, limitations that are likely to hinder therapeutic efficacy. In contrast to endogenous gene editing or genetic activation, I propose to develop a platform for epigenetic reprogramming of any locus of interest. As a proof-of-concept for this technology, I propose to engineer site-specific DNA binding module fusions with DNA demethylating enzymes for epigenetic induction of fetal hemoglobin (HbF) for therapy of sickle cell disease (SCD). SCD is caused by mutation of the adult -globin gene which forces red blood cells to sickle and occlude small blood vessels leading to exquisite pain and a wide range of medical complications. Fetal hemoglobin is normally silenced at birth by DNA methylation of the -globin locus as adult hemoglobin increases. Because small increases in HbF can cure this disease, SCD is an optimal application for developing epigenetic re-programming technologies. The major advantage of epigenetic engineering is that successful DNA demethylation of CpGs on both strands will lead to durable HbF-induction, not requiring continuous expression of ectopic proteins. This highly-innovative strategy has no precedent in the SCD literature. Development of this technology will lead to potent and durable HbF-induction therapy for SCD that will become the basis for an investigational new drug application. Moreover, this technology can be adapted to epigenetic reprogramming of other biochemical modifications including DNA methylation and histone acetylation and methylation. Each of these modifications could be targeted for therapeutic gene silencing or activation which will revolutionize molecularly-directed therapy for a variety of diseases.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Lnc'ing White Fat to Brown Fat Thermogenesis
  • 批准号:
    10064214
  • 项目类别:
  • 资助金额:
    $88.5万
  • 财政年份:
    2020
  • 负责人:
    CARL D NOVINA
  • 依托单位:
Defining LncRNA Function in normal and Shwachman Diamond Syndrome Myelopoiesis
  • 批准号:
    10320386
  • 项目类别:
  • 资助金额:
    $44.13万
  • 财政年份:
    2019
  • 负责人:
    CARL D NOVINA
  • 依托单位:
(PQD1) Evolution of vemurafenib resistance in circulating melanoma cells
  • 批准号:
    8851544
  • 项目类别:
  • 资助金额:
    $69.26万
  • 财政年份:
    2014
  • 负责人:
    CARL D NOVINA
  • 依托单位:
(PQD1) Evolution of vemurafenib resistance in circulating melanoma cells
  • 批准号:
    8687169
  • 项目类别:
  • 资助金额:
    $60.31万
  • 财政年份:
    2014
  • 负责人:
    CARL D NOVINA
  • 依托单位:
国内基金
海外基金
补阳还五汤通过AGE-RAGE通路调控脓毒症免疫失衡的机制与转化研究
芹菜素通过AGE-RAGE通路抑制干眼的炎症与氧化应激
  • 批准号:
    82505677
  • 项目类别:
    青年科学基金项目(C类)
  • 资助金额:
    30.00万元
  • 批准年份:
    2025
  • 负责人:
    吕雨霏
  • 依托单位:
麝香通心滴丸通过干预AGE-RAGE轴调节O-GlcNAc修饰发挥防治DCM作用的药效物质及机制研究
  • 批准号:
    82574874
  • 项目类别:
    面上项目
  • 资助金额:
    49.00万元
  • 批准年份:
    2025
  • 负责人:
    刘天华
  • 依托单位:
靶向递送一氧化碳调控AGE-RAGE级联反应促进糖尿病创面愈合研究
  • 批准号:
    JCZRQN202500010
  • 项目类别:
    省市级项目
  • 资助金额:
    --
  • 批准年份:
    2025
  • 负责人:
  • 依托单位: